KR101931896B1 - 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법 - Google Patents

에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법 Download PDF

Info

Publication number
KR101931896B1
KR101931896B1 KR1020177017050A KR20177017050A KR101931896B1 KR 101931896 B1 KR101931896 B1 KR 101931896B1 KR 1020177017050 A KR1020177017050 A KR 1020177017050A KR 20177017050 A KR20177017050 A KR 20177017050A KR 101931896 B1 KR101931896 B1 KR 101931896B1
Authority
KR
South Korea
Prior art keywords
dextromethorphan
bupropion
day
human
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177017050A
Other languages
English (en)
Korean (ko)
Other versions
KR20170088926A (ko
Inventor
헤리엇 타부테우
Original Assignee
안테씨프 바이오벤쳐스 투 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56014366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101931896(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/550,618 external-priority patent/US9198905B2/en
Priority claimed from US14/602,177 external-priority patent/US9402843B2/en
Application filed by 안테씨프 바이오벤쳐스 투 엘엘씨 filed Critical 안테씨프 바이오벤쳐스 투 엘엘씨
Priority to KR1020187036244A priority Critical patent/KR102253986B1/ko
Publication of KR20170088926A publication Critical patent/KR20170088926A/ko
Application granted granted Critical
Publication of KR101931896B1 publication Critical patent/KR101931896B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020177017050A 2014-11-21 2015-05-01 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법 Active KR101931896B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020187036244A KR102253986B1 (ko) 2014-11-21 2015-05-01 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US14/550,618 2014-11-21
US14/550,618 US9198905B2 (en) 2013-11-05 2014-11-21 Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US14/555,085 US9238032B2 (en) 2013-11-05 2014-11-26 Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US14/554,947 US20150126542A1 (en) 2013-11-05 2014-11-26 Compositions and Methods for Increasing the Metabolic Lifetime of Dextromethorphan and Related Pharmacodynamic Effects
US14/554,988 2014-11-26
US14/554,947 2014-11-26
US14/555,085 2014-11-26
US14/554,988 US9205083B2 (en) 2013-11-05 2014-11-26 Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
US14/602,177 US9402843B2 (en) 2013-11-05 2015-01-21 Compositions and methods of using threohydroxybupropion for therapeutic purposes
US14/602,177 2015-01-21
US14/604,397 2015-01-23
US14/604,397 US9168234B2 (en) 2013-11-05 2015-01-23 Bupropion as a modulator of drug activity
US14/617,624 2015-02-09
US14/617,624 US9486450B2 (en) 2013-11-05 2015-02-09 Hydroxybupropion and related compounds as modulators of drug plasma levels
US14/628,062 2015-02-20
US14/628,062 US9402844B2 (en) 2013-11-05 2015-02-20 Methods of modulating drug plasma levels using erythrohydroxybupropion
PCT/US2015/028901 WO2016081027A1 (en) 2014-11-21 2015-05-01 Methods of modulating drug plasma levels using erythrohydroxybupropion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187036244A Division KR102253986B1 (ko) 2014-11-21 2015-05-01 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법

Publications (2)

Publication Number Publication Date
KR20170088926A KR20170088926A (ko) 2017-08-02
KR101931896B1 true KR101931896B1 (ko) 2018-12-21

Family

ID=56014366

Family Applications (7)

Application Number Title Priority Date Filing Date
KR1020177017050A Active KR101931896B1 (ko) 2014-11-21 2015-05-01 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법
KR1020247005737A Active KR102822654B1 (ko) 2014-11-21 2015-05-01 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법
KR1020187036244A Active KR102253986B1 (ko) 2014-11-21 2015-05-01 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법
KR1020257019724A Pending KR20250092295A (ko) 2014-11-21 2015-05-01 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법
KR1020227008513A Active KR102524253B1 (ko) 2014-11-21 2015-05-01 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법
KR1020217014289A Active KR102376868B1 (ko) 2014-11-21 2015-05-01 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법
KR1020237012943A Active KR102640586B1 (ko) 2014-11-21 2015-05-01 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법

Family Applications After (6)

Application Number Title Priority Date Filing Date
KR1020247005737A Active KR102822654B1 (ko) 2014-11-21 2015-05-01 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법
KR1020187036244A Active KR102253986B1 (ko) 2014-11-21 2015-05-01 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법
KR1020257019724A Pending KR20250092295A (ko) 2014-11-21 2015-05-01 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법
KR1020227008513A Active KR102524253B1 (ko) 2014-11-21 2015-05-01 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법
KR1020217014289A Active KR102376868B1 (ko) 2014-11-21 2015-05-01 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법
KR1020237012943A Active KR102640586B1 (ko) 2014-11-21 2015-05-01 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법

Country Status (22)

Country Link
EP (2) EP3220909B2 (https=)
JP (5) JP6602863B2 (https=)
KR (7) KR101931896B1 (https=)
CN (2) CN111297860A (https=)
AU (4) AU2015350559C1 (https=)
CA (3) CA3232022A1 (https=)
CY (1) CY1123571T1 (https=)
DK (1) DK3220909T3 (https=)
ES (1) ES2835304T3 (https=)
HR (1) HRP20201855T1 (https=)
HU (1) HUE052609T2 (https=)
IL (4) IL297349B2 (https=)
LT (1) LT3220909T (https=)
MX (3) MX2017006653A (https=)
MY (1) MY189466A (https=)
PL (1) PL3220909T3 (https=)
PT (1) PT3220909T (https=)
RS (1) RS61113B1 (https=)
SG (2) SG11201704066VA (https=)
SI (1) SI3220909T1 (https=)
SM (1) SMT202000639T1 (https=)
WO (1) WO2016081027A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
CA3232022A1 (en) * 2014-11-21 2016-05-26 Antecip Bioventures Ii Llc Methods of modulating drug plasma levels using erythrohydroxybupropion
US12569479B2 (en) 2016-05-25 2026-03-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
SMT202600055T1 (it) * 2019-01-07 2026-03-09 Antecip Bioventures Ii Llc Combinazione di destrometorfano e bupropione per trattare la depressione in pazienti asiatici
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
EP4183391A4 (en) * 2020-07-20 2024-04-17 Shenzhen Salubris Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION AND ITS USE
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350756A (en) 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
WO2009006194A1 (en) 2007-06-28 2009-01-08 Avanir Pharmaceuticals Pharmaceutical compositions for the treatment of involuntary emotional expression disorder
WO2012118562A1 (en) 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
WO2013158680A2 (en) 2012-04-16 2013-10-24 Antecip Bioventures Ii Llc Compositions and methods comprising celecoxib or related compounds and dextromethorphan

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1986639A4 (en) * 2006-02-03 2010-04-28 Avanir Pharmaceuticals PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES
MY179696A (en) 2013-11-05 2020-11-11 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan
US9402843B2 (en) 2013-11-05 2016-08-02 Antecip Bioventures Ii Llc Compositions and methods of using threohydroxybupropion for therapeutic purposes
US9198905B2 (en) 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
CA3232022A1 (en) 2014-11-21 2016-05-26 Antecip Bioventures Ii Llc Methods of modulating drug plasma levels using erythrohydroxybupropion

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350756A (en) 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
WO2009006194A1 (en) 2007-06-28 2009-01-08 Avanir Pharmaceuticals Pharmaceutical compositions for the treatment of involuntary emotional expression disorder
WO2012118562A1 (en) 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
WO2013158680A2 (en) 2012-04-16 2013-10-24 Antecip Bioventures Ii Llc Compositions and methods comprising celecoxib or related compounds and dextromethorphan

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kotlyar, Michael 외. Inhibition of CYP2D6 Activity by Bupropion. Journal of Clinical Psychopharmacology. June 2005, Volume 25, Issue 3, pp. 226-229*

Also Published As

Publication number Publication date
MX2017006653A (es) 2017-10-31
RS61113B1 (sr) 2020-12-31
JP2020023527A (ja) 2020-02-13
JP2017535563A (ja) 2017-11-30
CN111297860A (zh) 2020-06-19
JP6842129B2 (ja) 2021-03-17
EP3220909A1 (en) 2017-09-27
KR102822654B1 (ko) 2025-06-18
AU2019201548B2 (en) 2020-11-26
HRP20201855T1 (hr) 2021-04-02
IL280905A (en) 2021-04-29
AU2015350559C1 (en) 2019-07-11
KR102253986B1 (ko) 2021-05-21
IL314982A (en) 2024-10-01
EP3220909B1 (en) 2020-09-02
MX2021001442A (es) 2023-01-05
CA3082645A1 (en) 2016-05-26
SMT202000639T1 (it) 2021-01-05
CA2968371A1 (en) 2016-05-26
WO2016081027A1 (en) 2016-05-26
AU2021200981B2 (en) 2024-06-20
ES2835304T3 (es) 2021-06-22
IL252417A0 (en) 2017-07-31
JP6602863B2 (ja) 2019-11-06
KR102640586B1 (ko) 2024-02-23
JP2023041862A (ja) 2023-03-24
JP2025105965A (ja) 2025-07-10
MX2023000320A (es) 2023-02-09
CY1123571T1 (el) 2022-03-24
PT3220909T (pt) 2020-12-07
AU2021200981A1 (en) 2021-03-11
MY189466A (en) 2022-02-15
EP3220909A4 (en) 2018-07-11
CN107205998A (zh) 2017-09-26
AU2019201548A1 (en) 2019-03-28
AU2019201548C1 (en) 2021-09-16
KR20230056795A (ko) 2023-04-27
SG11201704066VA (en) 2017-06-29
EP3220909B2 (en) 2026-02-18
KR20170088926A (ko) 2017-08-02
KR20180136003A (ko) 2018-12-21
IL252417B (en) 2021-03-25
KR20220038820A (ko) 2022-03-29
IL297349B2 (en) 2025-01-01
AU2015350559A1 (en) 2017-06-08
IL297349A (en) 2022-12-01
HUE052609T2 (hu) 2021-05-28
IL280905B (en) 2022-11-01
DK3220909T3 (da) 2020-11-23
LT3220909T (lt) 2021-01-25
JP7226839B2 (ja) 2023-02-21
KR102524253B1 (ko) 2023-04-20
HK1243323A1 (zh) 2018-07-13
CA3232022A1 (en) 2016-05-26
CA3082645C (en) 2024-04-16
SI3220909T1 (sl) 2021-01-29
IL280905B2 (en) 2023-03-01
KR20250092295A (ko) 2025-06-23
KR20240027872A (ko) 2024-03-04
AU2024219871A1 (en) 2024-10-10
CA2968371C (en) 2020-08-18
KR20210059788A (ko) 2021-05-25
JP2021066744A (ja) 2021-04-30
KR102376868B1 (ko) 2022-03-18
SG10201911873XA (en) 2020-02-27
IL297349B1 (en) 2024-09-01
EP3763372A1 (en) 2021-01-13
AU2015350559B2 (en) 2018-12-06
PL3220909T3 (pl) 2021-04-06

Similar Documents

Publication Publication Date Title
KR101931896B1 (ko) 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법
US9408815B2 (en) Bupropion as a modulator of drug activity
US9421176B1 (en) Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
JP2023129646A (ja) ブプロピオンおよびデキストロメトルファンの使用
JP2020023543A6 (ja) ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法
HK40030121A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
HK40063444A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HK40063443A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HK40064612A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
HK40015601A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170621

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170706

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180401

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20181127

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20181213

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20181217

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20181217

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20211122

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20211122

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20221123

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20221123

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20231128

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20241202

Start annual number: 7

End annual number: 7